CD19 and B-cell non-Hodgkin lymphoma: Several clinical trials are investigating mAbs targeting CD20 in combination with CD19-directed CAR NK cells, for the treatment of B cell lymphomas (NCT05618925, NCT05379647, NCT03579927, among others).